BackEagle Pharmaceuticals Overview

Eagle Pharmaceuticals Receivables

Track Eagle Pharmaceuticals's receivables ($120M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$115.14M
34.01% YoYΔ $29.22M vs prior year quarter

Peer average

Loading

Eagle Pharmaceuticals Receivables History

Loading

Eagle Pharmaceuticals vs. peers: Receivables Comparison

Loading

Eagle Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Eagle Pharmaceuticals (EGRX) FAQ

As of the most recent data (June 2023), EGRX shows a receivables of $120M. That compares with $86M in the prior-year period — up 34.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EGRX's receivables is now $120M (was $86M) — a 34.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Eagle Pharmaceuticals is outperforming or lagging.

Tracking EGRX's receivables over time shows whether Eagle Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $120M That compares with $86M in the prior-year period — up 34.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Eagle Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $120M) with ownership activity and broader fundamentals.

Eagle Pharmaceuticals's receivables is $120M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.